Limits...
Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea.

Yang SY, Lee HW, Lee YJ, Park SJ, Yoo KY, Kim HJ - Clin Mol Hepatol (2015)

Bottom Line: Common adverse events were hair loss (56.7%) and headache (51.0%).Common hematologic adverse events were neutropenia (22.1%), anemia (27.9%), and thrombocytopenia (3.8%).However, there were no serious adverse events such as bleeding.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastrohepatology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.

ABSTRACT

Background/aims: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. However, there are no published data on the efficacy of antiviral therapy in Korea. We assessed the safety and efficacy of combination therapy with peginterferon α-2a plus ribavirin for CHC in hemophilia.

Methods: Patients (n=115) were enrolled between March 2007 and December 2008. Seventy-seven patients were genotype 1 or 6, and 38 patients were genotype 2 or 3. We evaluated rapid virologic responses (RVRs), early virologic response (EVRs), end-of-treatment response (ETRs), sustained virologic response (SVRs), and relapses. Safety evaluations included adverse events and laboratory tests.

Results: Eleven patients were excluded from the study because they had been treated previously. Among the remaining 104 treatment-naïve patients, RVR was achieved in 64 (60.6%), ETR was achieved in 95 (91.3%), and SVR was achieved in 89 (85.6%). Relapse occurred in eight patients (8.9%). Common adverse events were hair loss (56.7%) and headache (51.0%). Common hematologic adverse events were neutropenia (22.1%), anemia (27.9%), and thrombocytopenia (3.8%). However, there were no serious adverse events such as bleeding. RVR was the only predictor of SVR in multivariate analysis.

Conclusions: Peginterferon α-2a plus ribavirin combination treatment produced a favorable response rate in CHC patients with hemophilia without serious adverse events.

No MeSH data available.


Related in: MedlinePlus

Virological response in treatment-naïve patients. Note: Response was determined based on the results of a treatment period using an intention-to-treat analysis. RVR, rapid virologic response; ETR, end-oftreatment response; SVR, sustained virologic response.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4493355&req=5

Figure 2: Virological response in treatment-naïve patients. Note: Response was determined based on the results of a treatment period using an intention-to-treat analysis. RVR, rapid virologic response; ETR, end-oftreatment response; SVR, sustained virologic response.

Mentions: Figure 2 shows the virological response by treatment duration for each genotype. As shown, the SVR rate of all patients was 85.6% (82.4% in genotypes 1/6 and 91.7% in genotypes 2/3). The EVR rate was similar between these two groups (P>0.05). However, we found that the RVR rate was significantly lower in genotype 1 and genotype 6.


Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea.

Yang SY, Lee HW, Lee YJ, Park SJ, Yoo KY, Kim HJ - Clin Mol Hepatol (2015)

Virological response in treatment-naïve patients. Note: Response was determined based on the results of a treatment period using an intention-to-treat analysis. RVR, rapid virologic response; ETR, end-oftreatment response; SVR, sustained virologic response.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4493355&req=5

Figure 2: Virological response in treatment-naïve patients. Note: Response was determined based on the results of a treatment period using an intention-to-treat analysis. RVR, rapid virologic response; ETR, end-oftreatment response; SVR, sustained virologic response.
Mentions: Figure 2 shows the virological response by treatment duration for each genotype. As shown, the SVR rate of all patients was 85.6% (82.4% in genotypes 1/6 and 91.7% in genotypes 2/3). The EVR rate was similar between these two groups (P>0.05). However, we found that the RVR rate was significantly lower in genotype 1 and genotype 6.

Bottom Line: Common adverse events were hair loss (56.7%) and headache (51.0%).Common hematologic adverse events were neutropenia (22.1%), anemia (27.9%), and thrombocytopenia (3.8%).However, there were no serious adverse events such as bleeding.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastrohepatology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.

ABSTRACT

Background/aims: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. However, there are no published data on the efficacy of antiviral therapy in Korea. We assessed the safety and efficacy of combination therapy with peginterferon α-2a plus ribavirin for CHC in hemophilia.

Methods: Patients (n=115) were enrolled between March 2007 and December 2008. Seventy-seven patients were genotype 1 or 6, and 38 patients were genotype 2 or 3. We evaluated rapid virologic responses (RVRs), early virologic response (EVRs), end-of-treatment response (ETRs), sustained virologic response (SVRs), and relapses. Safety evaluations included adverse events and laboratory tests.

Results: Eleven patients were excluded from the study because they had been treated previously. Among the remaining 104 treatment-naïve patients, RVR was achieved in 64 (60.6%), ETR was achieved in 95 (91.3%), and SVR was achieved in 89 (85.6%). Relapse occurred in eight patients (8.9%). Common adverse events were hair loss (56.7%) and headache (51.0%). Common hematologic adverse events were neutropenia (22.1%), anemia (27.9%), and thrombocytopenia (3.8%). However, there were no serious adverse events such as bleeding. RVR was the only predictor of SVR in multivariate analysis.

Conclusions: Peginterferon α-2a plus ribavirin combination treatment produced a favorable response rate in CHC patients with hemophilia without serious adverse events.

No MeSH data available.


Related in: MedlinePlus